Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy

Next Previous
X
Search
Trial Profile

BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone (Primary)
  • Indications Rhinosinusitis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Acronyms BEACON
  • Sponsors Lyra Therapeutics

    • Most Recent Events

    • 27 Sep 2024 According to a Lyra Therapeutics media release, the Company will present results from this study at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place September 27-28 in Miami. The oral presentation will be delivered on September 29th at 1:06 p.m. ET.
    • 30 Apr 2024 According to a Lyra Therapeutics media release, an end-of-Phase 2 meeting for LYR-220 with the FDA is anticipated in the second half of 2024.
    • 30 Apr 2024 According to a Lyra Therapeutics media release, company plans to present additional secondary endpoint data from the BEACON Phase 2 clinical trial of LYR-220 at the 2024 Combined Otolaryngology Spring Meetings (COSM) being held May 15-19, 2024 in Chicago, IL.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top